TFF Pharmaceuticals IncNASDAQ:TFFP
- LAST PRICE7.5200
- TODAY'S CHANGE (%)-0.2100 (-2.7167%)
- Bid / Lots7.5800/ 1
- Ask / Lots9.8800/ 1
- Open / Previous Close7.6800 / 7.7300
- Day Range
- 52 Week Range
- Volume77,338
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TFFP |
|---|---|---|
| 09:32 ET | 5746 | 7.68 |
| 09:36 ET | 265 | 7.6591 |
| 09:41 ET | 2074 | 7.59 |
| 09:45 ET | 2500 | 7.5104 |
| 09:50 ET | 200 | 7.56 |
| 09:52 ET | 100 | 7.55 |
| 09:54 ET | 1500 | 7.55 |
| 10:01 ET | 100 | 7.53 |
| 10:14 ET | 555 | 7.4801 |
| 10:15 ET | 200 | 7.5 |
| 10:21 ET | 1500 | 7.62 |
| 10:24 ET | 100 | 7.635 |
| 10:42 ET | 3543 | 7.62 |
| 10:44 ET | 4968 | 7.56 |
| 10:46 ET | 6620 | 7.5122 |
| 10:51 ET | 200 | 7.69 |
| 10:55 ET | 240 | 7.56 |
| 11:02 ET | 300 | 7.59 |
| 11:04 ET | 800 | 7.69 |
| 11:11 ET | 100 | 7.6063 |
| 11:18 ET | 600 | 7.59 |
| 11:22 ET | 500 | 7.585 |
| 11:24 ET | 197 | 7.57 |
| 11:29 ET | 700 | 7.57 |
| 11:42 ET | 300 | 7.5782 |
| 11:44 ET | 100 | 7.5799 |
| 11:49 ET | 300 | 7.52 |
| 11:56 ET | 100 | 7.52 |
| 12:07 ET | 1061 | 7.5 |
| 12:14 ET | 669 | 7.4868 |
| 12:32 ET | 300 | 7.471 |
| 12:48 ET | 9877 | 7.57 |
| 12:50 ET | 1900 | 7.54 |
| 12:54 ET | 200 | 7.6 |
| 01:01 ET | 4956 | 7.6398 |
| 01:15 ET | 200 | 7.9 |
| 01:37 ET | 100 | 7.65 |
| 01:39 ET | 425 | 7.63 |
| 01:46 ET | 400 | 7.65 |
| 01:53 ET | 100 | 7.6 |
| 02:13 ET | 5229 | 7.55 |
| 02:56 ET | 100 | 7.7 |
| 03:14 ET | 985 | 7.59 |
| 03:16 ET | 300 | 7.5705 |
| 03:43 ET | 100 | 7.525 |
| 03:45 ET | 200 | 7.54 |
| 03:48 ET | 461 | 7.505 |
| 03:54 ET | 5100 | 7.51 |
| 03:57 ET | 300 | 7.51 |
| 03:59 ET | 4195 | 7.52 |
Oct 14, 2021
BRIEF-TFF Pharmaceuticals And Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation Of Covid-19 Antibody
Sep 23, 2021
TFF Pharma Says Inhaled Tacrolimus Powder Shows Potential in Lung Transplant Patients
TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TFF Pharmaceuticals Inc | 190.8M | -7.2x | --- |
Adverum Biotechnologies Inc | 191.3M | -1.4x | --- |
Corvus Pharmaceuticals Inc | 189.6M | -189.1x | --- |
Aptose Biosciences Inc | 192.8M | -3.3x | --- |
PhaseBio Pharmaceuticals Inc | 192.2M | -1.2x | --- |
Galectin Therapeutics Inc | 194.5M | -6.6x | --- |
Company Information
TFF Pharmaceuticals, Inc. is an early stage biopharmaceutical company. The Company is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Voriconazole Inhalation Powder (VIP), TFF Tacrolimus Inhalation Powder (TIP) and Triple Combination. It is developing TFF VIP to treat invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF VIP is being developed as an inhaled dry powder drug. It is developing TFF TIP, a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. It is developing Triple Combination, a dry powder drug combination to treat chronic obstructive pulmonary disease (COPD) and asthma. Its other dry powder products include Inhaled SARS-CoV2 Monoclonal Antibody, Niclosamide Inhalation Powder, Cannabidiol (CBD) and Vaccines.
Contact Information
- Headquarters
- 2600 Via Fortuna Ste 360AUSTIN, TX, United States 78746-7983
- Phone
- ---
- Fax
- 302-655-5049
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $190.8M |
|---|---|
Revenue (TTM) | $26.2K |
Shares Outstanding | 25.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.05 |
Book Value | $1.66 |
P/E Ratio | -7.2x |
Price/Sales (TTM) | 7,290.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -91,747.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
